Abstract
Beatriz Gros, Lauranne A. A. P. Derikx, Marie Truyens, Nathan Grellier, Joseph Sleiman, Piotr Eder, Konstantinos Karmiris, Ignacio Catalán‐Serra, Sang Hyoung Park, Mohammed Nabil Quraishi, Brigida Barberio
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1053/j.gastro.2011.01.055
10.1053/j.gastro.2011.01.055
10.1136/gutjnl-2011-301971
10.1136/gutjnl-2011-301971
10.1093/ecco-jcc/jjab141
10.1093/ecco-jcc/jjab141
Surgery in a Population-Based Cohort of Crohn’s Disease From Olmsted County, Minnesota (1970–2004)
10.1038/ajg.2012.298 · 2012
10.1038/s41575-024-01035-7
10.1038/s41575-024-01035-7
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
10.1111/apt.18294 · 2024
10.3390/jcm14051536
10.3390/jcm14051536
Early Crohn’s disease: can we change the disease course?
10.1038/s41575-025-01072-w · 2025
Rheumatoid arthritis
10.1016/s0140-6736(23)01525-8 · 2023
10.1136/annrheumdis-2016-210602
10.1136/annrheumdis-2016-210602
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts
10.1136/annrheumdis-2014-206047 · 2015
10.1136/rmdopen-2018-000870
10.1136/rmdopen-2018-000870
Very early rheumatoid arthritis is the major predictor of major outcomes: Clinical ACR remission and radiographic non-progression
10.1136/ard.2010.142729 · 2011
10.1093/rheumatology/keh199
10.1093/rheumatology/keh199
10.1002/art.22353
10.1002/art.22353
Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review
10.1016/j.jaut.2026.103526 · 2026
10.1053/j.gastro.2020.10.065
10.1053/j.gastro.2020.10.065
10.1097/00054725-200207000-00002
10.1097/00054725-200207000-00002
10.1038/ajg.2009.579
10.1038/ajg.2009.579
10.1002/ibd.21417
10.1002/ibd.21417
10.1093/ecco-jcc/jjaf203
10.1093/ecco-jcc/jjaf203
P0472 Impact of diagnostic delay on disease progression and advanced treatment requirements in a real-world Inflammatory Bowel Disease cohort
2026
Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts
10.1093/gastro/goag013 · 2026
10.1053/j.gastro.2005.12.019
10.1053/j.gastro.2005.12.019
10.3390/jcm14227984
10.3390/jcm14227984
10.1053/j.gastro.2020.12.031
10.1053/j.gastro.2020.12.031
10.1053/j.gastro.2020.12.031
10.1053/j.gastro.2020.12.031
10.1016/j.cgh.2025.10.022
10.1016/j.cgh.2025.10.022
10.1053/j.gastro.2013.06.009
10.1053/j.gastro.2013.06.009
10.1053/j.gastro.2013.04.048
10.1053/j.gastro.2013.04.048
10.1016/s0140-6736(02)08512-4
10.1016/s0140-6736(02)08512-4
10.1053/j.gastro.2006.11.041
10.1053/j.gastro.2006.11.041
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial
10.1016/s0140-6736(08)60304-9 · 2008
10.1093/ecco-jcc/jjy014
10.1093/ecco-jcc/jjy014
10.1053/j.gastro.2018.01.004
10.1053/j.gastro.2018.01.004
10.1016/j.cgh.2021.11.030
10.1016/j.cgh.2021.11.030
10.1053/j.gastro.2008.07.069
10.1053/j.gastro.2008.07.069
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease
10.1053/j.gastro.2005.01.048 · 2005
10.1016/s0140-6736(15)00068-9
10.1016/s0140-6736(15)00068-9
Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy
10.1093/crocol/otae040 · 2024
10.1016/s0140-6736(22)01193-x
10.1016/s0140-6736(22)01193-x · doi-reference
10.1016/j.cgh.2024.01.026
10.1016/j.cgh.2024.01.026 · doi-reference
10.1136/gutjnl-2023-330000
10.1136/gutjnl-2023-330000 · doi-reference
10.1016/s2468-1253(19)30340-1
10.1016/s2468-1253(19)30340-1 · doi-reference
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey
10.1002/ueg2.70091 · doi-reference
How Should an IBD Prevention Trial Be Designed?
10.1093/ibd/izaf212 · doi-reference
Review article: Prevention of inflammatory bowel disease—The path forward
10.1111/apt.18263 · doi-reference
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
10.1016/s2468-1253(24)00439-4 · doi-reference
Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?
10.1053/j.gastro.2021.07.051 · doi-reference
Combination therapies: the next major frontier in IBD management
10.1038/s41575-023-00839-3 · doi-reference
Understanding and Addressing the Psychological Burden of IBD
10.1093/ecco-jcc/jjab130 · doi-reference
10.1093/ecco-jcc/jjz160
10.1093/ecco-jcc/jjz160 · doi-reference
10.1111/apt.70181
10.1111/apt.70181 · doi-reference
Seeing the whole picture: Inflammatory bowel disease complications and extraintestinal manifestations on cross‐sectional imaging
10.1002/ueg2.12619 · doi-reference
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease
10.1093/ecco-jcc/jjae145 · doi-reference
10.3390/jcm9082646
10.3390/jcm9082646 · doi-reference
Methodological pitfalls in mild Crohn’s disease clinical trials
10.1016/j.medj.2026.101042 · doi-reference
10.1093/ecco-jcc/jjw126
10.1093/ecco-jcc/jjw126 · doi-reference
10.1016/j.cgh.2025.09.014
10.1016/j.cgh.2025.09.014 · doi-reference
10.1016/s2468-1253(21)00393-9
10.1016/s2468-1253(21)00393-9 · doi-reference
10.1136/gutjnl-2023-329963
10.1136/gutjnl-2023-329963 · doi-reference
Apples and oranges? Comparison of early ileocolic resection and medical treatment for Crohn’s disease: a systematic review and meta-analysis
10.1093/ecco-jcc/jjaf218 · doi-reference
Upfront medical or surgical treatment in Crohn’s disease
10.1016/s2468-1253(26)00078-6 · doi-reference
Long-term comparative outcomes after ileocecal resection for inflammatory versus complicated Crohn’s disease. A multicenter, retrospective study (Crohn’s-Urg)
10.1016/j.dld.2025.07.009 · doi-reference
Early ileal resection in Crohn’s disease is not associated with severe long‐term outcomes: The ERIC study
10.1111/apt.18247 · doi-reference
Early Ileocecal Resection for Crohn’s Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study
10.1053/j.gastro.2023.05.051 · doi-reference
10.1016/s2468-1253(25)00374-7
10.1016/s2468-1253(25)00374-7 · doi-reference
10.1016/s2468-1253(17)30248-0
10.1016/s2468-1253(17)30248-0 · doi-reference
10.1093/ecco-jcc/jjv184
10.1093/ecco-jcc/jjv184 · doi-reference
10.1093/ibd/izag114
10.1093/ibd/izag114 · doi-reference
Vedolizumab treatment outcomes in early versus late Crohn’s disease
10.1016/s2468-1253(25)00349-8 · doi-reference
10.1056/nejmoa2314585
10.1056/nejmoa2314585 · doi-reference
10.1016/j.coph.2025.102583
10.1016/j.coph.2025.102583 · doi-reference
Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
10.1016/j.gastha.2024.02.008 · doi-reference
10.3390/biomedicines13020391
10.3390/biomedicines13020391 · doi-reference
Vedolizumab in early and late Crohn’s disease (LOVE-CD): a phase 4 open-label cohort study
10.1016/s2468-1253(25)00233-x · doi-reference
10.1016/j.cgh.2026.06.029
10.1016/j.cgh.2026.06.029 · doi-reference
10.1136/gutjnl-2024-333280
10.1136/gutjnl-2024-333280 · doi-reference
10.1093/ibd/izag073
10.1093/ibd/izag073 · doi-reference
10.1093/ecco-jcc/jjae089
10.1093/ecco-jcc/jjae089 · doi-reference